ATE488596T1 - Adenovirus/alphavirus-hybrid-vektor zur effektiven verabreichung und expression von therapeutischen genen in tumorzellen - Google Patents

Adenovirus/alphavirus-hybrid-vektor zur effektiven verabreichung und expression von therapeutischen genen in tumorzellen

Info

Publication number
ATE488596T1
ATE488596T1 AT05750184T AT05750184T ATE488596T1 AT E488596 T1 ATE488596 T1 AT E488596T1 AT 05750184 T AT05750184 T AT 05750184T AT 05750184 T AT05750184 T AT 05750184T AT E488596 T1 ATE488596 T1 AT E488596T1
Authority
AT
Austria
Prior art keywords
sequence
hybrid vector
adenoviral
adenovirus
expression
Prior art date
Application number
AT05750184T
Other languages
English (en)
Inventor
Cheng Qian
Min Guan
Picazo Cristian Smerdou
Valtuena Jesus Prieto
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of ATE488596T1 publication Critical patent/ATE488596T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05750184T 2004-05-20 2005-05-18 Adenovirus/alphavirus-hybrid-vektor zur effektiven verabreichung und expression von therapeutischen genen in tumorzellen ATE488596T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401219A ES2292271B1 (es) 2004-05-20 2004-05-20 Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
PCT/ES2005/000277 WO2005112541A2 (es) 2004-05-20 2005-05-18 Un vector híbrido adenovirus-alfavirus para la administración eficaz y expresión de genes terapéuticos en células tumorales

Publications (1)

Publication Number Publication Date
ATE488596T1 true ATE488596T1 (de) 2010-12-15

Family

ID=35428710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05750184T ATE488596T1 (de) 2004-05-20 2005-05-18 Adenovirus/alphavirus-hybrid-vektor zur effektiven verabreichung und expression von therapeutischen genen in tumorzellen

Country Status (20)

Country Link
US (1) US7850957B2 (de)
EP (1) EP1760153B1 (de)
JP (1) JP4767945B2 (de)
CN (1) CN100580085C (de)
AT (1) ATE488596T1 (de)
AU (2) AU2005244625A1 (de)
BR (1) BRPI0510905A (de)
CA (1) CA2567455A1 (de)
CY (1) CY1111496T1 (de)
DE (1) DE602005024805D1 (de)
DK (1) DK1760153T3 (de)
ES (2) ES2292271B1 (de)
HR (1) HRP20110059T1 (de)
MX (1) MXPA06013277A (de)
PL (1) PL1760153T3 (de)
PT (1) PT1760153E (de)
RS (1) RS51559B (de)
RU (1) RU2394104C2 (de)
SI (1) SI1760153T1 (de)
WO (1) WO2005112541A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
EP1900749A1 (de) * 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
WO2008065225A2 (es) * 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vector viral y sus aplicaciones
EP2550359B1 (de) 2010-03-23 2017-08-09 Intrexon Corporation Vektoren zur bedingten expression therapeutischer proteine, wirtszellen mit diesen vektoren und verwendungen davon
CN101966341B (zh) * 2010-09-30 2012-06-27 中国农业科学院哈尔滨兽医研究所 腺病毒/甲病毒复制子嵌合载体猪瘟疫苗及其应用
CN103339262A (zh) * 2010-10-28 2013-10-02 弗吉尼亚联邦大学 具有治疗作用的癌症成像:治疗诊断学
DK2951309T3 (en) * 2013-02-01 2019-04-23 Selexis Sa INCREASED TRANSGEN EXPRESSION AND PROCESSING
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP2878674A1 (de) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stabile Episomen auf Basis von nichtintegrativen lentiviralen Vektoren
CN106367401A (zh) * 2016-08-29 2017-02-01 黄朝述 具有基因协同元件的病毒及其应用
CN118718020A (zh) * 2016-12-09 2024-10-01 基因药物株式会社 含有表达细胞外基质的降解因子的重组腺病毒的抗癌组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5144482A (en) 1991-05-13 1992-09-01 Gould Dennis R Three dimensional viewing apparatus including a stack of transparent plates and related method
WO1995016772A1 (en) * 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
JP2002514904A (ja) * 1996-06-20 2002-05-21 メルク エンド カンパニー インコーポレーテッド 肥満に対する遺伝子治療
AU729690B2 (en) * 1996-10-10 2001-02-08 Henrik Garoff Alphavirus-retrovirus vectors
EP0956052B1 (de) * 1996-11-19 2005-04-13 University Of Alabama, Birmingham Research Foundation Chimäres retrovirus/adenovirus system
WO1998046778A1 (en) * 1997-04-11 1998-10-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Transgenomic viruses and the use thereof
CA2309835A1 (en) * 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors
AU749345B2 (en) * 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
WO1999032647A1 (en) * 1997-12-23 1999-07-01 Introgene B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
EP1084236A4 (de) * 1998-06-09 2003-04-02 Merck & Co Inc Adenovirale vektoren für die gentherapy
GB9817660D0 (en) * 1998-08-13 1998-10-07 Angeletti P Ist Richerche Bio Adenoviral vectors encoding erythropoietin and their use in gene therapy
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
CA2360796A1 (en) * 1999-02-04 2000-08-10 Merck & Co., Inc. Improved helper dependent vector system for gene therapy
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
AU4370401A (en) * 2000-03-24 2001-10-08 Cell Genesys Inc Methods of treating neoplasia with combinations of target cell-specific adenovirus, chemotherapy and radiation
DE10056210A1 (de) * 2000-11-13 2002-05-29 Arimedes Biotechnology Gmbh Virales Expressionssystem
US20020164624A1 (en) * 2001-02-12 2002-11-07 Waldemar Debinski VEGF-D expression in brain cancer
WO2002079447A2 (en) * 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
CA2392863A1 (en) * 2002-07-08 2004-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A high capacity recombinant adenoviral vector for treatment of hemophilia a

Also Published As

Publication number Publication date
DE602005024805D1 (de) 2010-12-30
PT1760153E (pt) 2010-12-23
JP2007537742A (ja) 2007-12-27
US7850957B2 (en) 2010-12-14
RS51559B (sr) 2011-06-30
MXPA06013277A (es) 2007-02-28
WO2005112541A3 (es) 2006-03-23
US20070224170A1 (en) 2007-09-27
CN100580085C (zh) 2010-01-13
SI1760153T1 (sl) 2011-02-28
RU2006145306A (ru) 2008-06-27
RU2394104C2 (ru) 2010-07-10
CN1957086A (zh) 2007-05-02
JP4767945B2 (ja) 2011-09-07
EP1760153A2 (de) 2007-03-07
WO2005112541A2 (es) 2005-12-01
CY1111496T1 (el) 2015-08-05
CA2567455A1 (en) 2005-12-01
ES2292271B1 (es) 2009-02-16
DK1760153T3 (da) 2011-02-21
HRP20110059T1 (hr) 2011-03-31
AU2005244625A1 (en) 2005-12-01
ES2356322T3 (es) 2011-04-06
EP1760153B1 (de) 2010-11-17
AU2010214637A1 (en) 2010-09-16
AU2010214637B2 (en) 2012-04-26
ES2292271A1 (es) 2008-03-01
BRPI0510905A (pt) 2007-11-06
PL1760153T3 (pl) 2011-04-29

Similar Documents

Publication Publication Date Title
CY1111496T1 (el) Υβριδικος φορεας αδενοϊου/αλφαϊου για την αποτελεσματικη χορηγηση και εκφραση θεραπευτικων γονιδιων σε κυτταρα ογκου
JP2019088334A5 (de)
CN112584849A (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
JP2007516696A5 (de)
MX2021011039A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
UA85371C2 (ru) Модифицированный вирус коровьей оспы ankara для вакцинации новорожденных
CA2229631A1 (en) Gene therapy using ovine adenoviral vectors
CN103614416A (zh) 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
EA010434B1 (ru) Способ получения цитотоксических лимфоцитов
KR102428606B1 (ko) 향상된 유전자 전달 방법
CA3156954A1 (en) Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
Shen et al. A modified HSV-1 oncolytic virus reconciles antiviral and antitumor immunity via promoting IFNβ expression and inhibiting PKR
WO2023283342A3 (en) Oligonucleotides and viral untranslated region (utr) for increasing expression of target genes and proteins
WO2005019450A1 (ja) 細胞傷害性リンパ球の製造方法
MX2022011806A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher.
RU2006105195A (ru) Синтетический ген, кодирующий человеческий антиген эпидермального фактора роста 2/neu, и его применение
JP2007504840A5 (de)
JP2022536122A5 (de)
EP2114459A1 (de) Rekombinante virale vektoren für vorbeugung und schutz gegen alphavirus-infektion
RU2007147422A (ru) Способ рекомбинантного получения стимулирующего эритропоэз белка
CN117487768A (zh) 工程化单纯疱疹病毒
CN111500632B (zh) 表达st13和trail的溶瘤腺病毒构建及其应用
RU2507265C2 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pCI-UB-POLYEPI, СОДЕРЖАЩАЯ ЭПИТОПЫ ОПУХОЛЬ-АССОЦИИРОВАННЫХ АНТИГЕНОВ ДЛЯ КОЛОРЕКТАЛЬНОГО РАКА, И СПОСОБ ЕЕ ПРИМЕНЕНИЯ ДЛЯ СТИМУЛЯЦИИ СПЕЦИФИЧЕСКОГО ПРОТИВООПУХОЛЕВОГО ИММУННОГО ОТВЕТА ПРОТИВ КЛЕТОК КОЛОРЕКТАЛЬНОГО РАКА
CN117083390A (zh) 用于治疗癌症的腺病毒

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1760153

Country of ref document: EP